Hirsch Joshua R, Gales Jordan M, Giorgberidze Irakli, Afshar Hamid
Section of Cardiology, Baylor College of Medicine, Houston, Texas.
Department of Cardiology, The Texas Heart Institute at Baylor St Luke's Medical Center, Houston, Texas.
Tex Heart Inst J. 2025 Mar 12;52(1):e248495. doi: 10.14503/THIJ-24-8495. eCollection 2025 Jan-Jun.
The AVEIR DR (Abbott Medical) was the first dual-chamber leadless pacing system approved by the US Food and Drug Administration. Many patients with sinus node dysfunction have physiologically normal atrioventricular conduction, so an atrial-only pacing system may be appropriate for them. Three patients with symptomatic sinus node dysfunction underwent device implantation with electrophysiologic study, including incremental atrial pacing until loss of 1:1 atrioventricular conduction (atrioventricular Wenckebach cycle length) and His-ventricular interval measurement. If the atrioventricular Wenckebach cycle length was no more than 400 milliseconds and the His-ventricular interval measurement was no more than 55 milliseconds, single-chamber atrial implantation was deemed appropriate. Each patient displayed a different response to atrioventricular conduction testing, demonstrating how electrophysiologic study before device implantation may identify patients for whom atrial-only pacing is not appropriate.
AVEIR DR(雅培医疗)是首个获得美国食品药品监督管理局批准的双腔无导线起搏系统。许多窦房结功能障碍患者的房室传导在生理上是正常的,因此仅心房起搏系统可能适合他们。三名有症状的窦房结功能障碍患者接受了设备植入及电生理研究,包括递增性心房起搏直至1:1房室传导丧失(房室文氏周期长度)以及希氏束-心室间期测量。如果房室文氏周期长度不超过400毫秒且希氏束-心室间期测量不超过55毫秒,则认为单腔心房植入是合适的。每位患者对房室传导测试都表现出不同的反应,这表明在设备植入前进行电生理研究如何能够识别出不适合仅心房起搏的患者。